H.C. Wainwright 25th Annual Global Investment Conference

Live on Tuesday, 9/12 at 3:00 PM (Eastern Standard Time)

PXMD Business Update

Business Briefing: SIGNIFICANT PHASE 3 PAX-HAT-301 STUDY RESULTS; PROGRESSING TOWARD START OF MULTI-CENTEREDCLINICAL TRIALS IN ASD

Positive Top Line Results

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

PaxMedica Grants Exclusive Pharmacy Distribution Rights

Exclusive pharmacy distribution agreement for PaxMedica’s lead pipeline asset, PAX-101, granted to Vox Nova LLC

The BRAIN Foundation Presents: Suramin for Autism

PaxMedica CEO Interviewed by The BRAIN Foundation

PaxMedica Rings the NASDAQ Closing Bell

PaxMedica Celebrates Autism Awareness Month

Discussing Priority Review Vouchers With Chief Medical Officer Stefan Schwabe

Discussing Priority Review Vouchers With Chief Medical Officer Stefan Schwabe

Paxmedica Diving into the Investor Presentation with CEO Howard Weisman

PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.

PaxMedica Holds Meeting of Scientific Advisory Board

Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S.

PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome

Study has been approved by the South African Health Authority for individuals with documented COVID-19 infections who develop debilitating physical and neuropsychiatric symptoms that persist for...

PaxMedica selected by American Academy of Child and Adolescent Psychiatry (AACAP) to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) in the Research Pipeline Program

David Hough, MD, CMO of PaxMedica will present trial results at the upcoming AACAP Annual Meeting during the “Research Pipeline: New Findings on Diagnostics and Therapeutics” program...

PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD)

PAX-101 demonstrated sustained improvements over placebo in the trial’s primary and several secondary endpoints and a favorable safety and tolerability profile

PaxMedica Receives FDA Orphan Drug Designation for Use of PAX-101 (IV suramin) in a Rare Tropical Disease

Company Pursuing Development of PAX-101 as Treatment for Autism Spectrum Disorder and Other Neurodevelopmental Conditions